You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Netherlands temporarily halts AstraZeneca Covid-19 vaccine for under-60s

The Netherlands has temporarily halted the use of the AstraZeneca Covid-19 vaccine for people under the age of 60, the Ministry of Health, Welfare and Sport.

Coronavirus Vaccine | Coronavirus Tests | Coronavirus

IANS  |  The Hague 

AstraZeneca, Coronavirus vaccine
Photo: Shutterstock

The Netherlands has temporarily halted the use of the AstraZeneca Covid-19 vaccine for people under the age of 60, the Ministry of Health, Welfare and Sport.

The decision on Friday was prompted by possible blood clotting problems as a side effect of the vaccine, reports Xinhua news agency.

Earlier on in the day, the Lareb side effects centre reported that after injecting some 400,000 doses of the AstraZeneca vaccine, five reports have been received concerning women aged 25-65 who developed thrombosis in combination with a reduced platelet count.

One of these five women died after developing an extensive pulmonary embolism within 10 days of the vaccination.

The outgoing Dutch Health Minister Hugo de Jonge said there should be no doubt whatsoever about the safety of vaccines.

"The crucial question is still whether it concerns complaints after vaccination or due to vaccination," he said in a statement, adding that "it is wise to press the pause button now as a precaution".

The Minister wrote in a letter to Parliament that he took this decision pending a further judgment by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency.

The committee is expected to come with further information about the AstraZeneca vaccine.

Besides the Netherlands, vaccination is underway in an increasing number of countries with the already-authorised vaccines.




(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, April 03 2021. 10:00 IST